Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction

[1]  Chiew Y Wong,et al.  Heart failure with preserved ejection fraction: an insight into its prevalence, predictors, and implications of early detection. , 2015, Reviews in cardiovascular medicine.

[2]  T. Yoo,et al.  Diastolic Dysfunction Is an Independent Predictor of Cardiovascular Events in Incident Dialysis Patients with Preserved Systolic Function , 2015, PloS one.

[3]  F. Burzotta,et al.  Dual role of circulating endothelial progenitor cells in stent struts endothelialisation and neointimal regrowth: a substudy of the IN-PACT CORO trial. , 2015, Cardiovascular revascularization medicine : including molecular interventions.

[4]  H. Gullu,et al.  Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease. , 2015, Microvascular research.

[5]  Jennifer K. Miller,et al.  Quantitative Proteomics for Cardiac Biomarker Discovery Using Isoproterenol-Treated Nonhuman Primates , 2014, Journal of proteome research.

[6]  Christopher Gerner,et al.  A platelet protein biochip rapidly detects an Alzheimer’s disease-specific phenotype , 2014, Acta Neuropathologica.

[7]  K. Boheler,et al.  High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry. , 2014, Journal of visualized experiments : JoVE.

[8]  Jie Liu,et al.  Effects of Advanced Glycation End Products on Calcium Handling in Cardiomyocytes , 2014, Cardiology.

[9]  L. de las Fuentes,et al.  Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. , 2014, Journal of the American College of Cardiology.

[10]  P. LaViolette,et al.  Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. , 2014, Physiological genomics.

[11]  J. Dyck,et al.  Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology , 2014, PloS one.

[12]  Hui-Hua Li,et al.  S100a8/a9 Released by CD11b+Gr1+ Neutrophils Activates Cardiac Fibroblasts to Initiate Angiotensin II–Induced Cardiac Inflammation and Injury , 2014, Hypertension.

[13]  A. Schmaier,et al.  Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. , 2014, The Journal of clinical investigation.

[14]  Thomas Eschenhagen,et al.  Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. , 2014, American journal of physiology. Heart and circulatory physiology.

[15]  J. Kocot,et al.  The many “faces” of copper in medicine and treatment , 2014, BioMetals.

[16]  J. Kocot,et al.  The many “faces” of copper in medicine and treatment , 2014, BioMetals.

[17]  U. Walter,et al.  What can proteomics tell us about platelets? , 2014, Circulation research.

[18]  B. Hedblad,et al.  Plasma S100A8/A9 Correlates With Blood Neutrophil Counts, Traditional Risk Factors, and Cardiovascular Disease in Middle-Aged Healthy Individuals , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Y. Takeishi,et al.  Phosphodiesterase 3A1 protects the heart against angiotensin II-induced cardiac remodeling through regulation of transforming growth factor-β expression. , 2014, International heart journal.

[20]  O. Cotoi,et al.  S100A8 and S100A9: DAMPs at the Crossroads between Innate Immunity, Traditional Risk Factors, and Cardiovascular Disease , 2013, Mediators of inflammation.

[21]  Xin-Hua Feng,et al.  Zinc Finger Protein 451 Is a Novel Smad Corepressor in Transforming Growth Factor-β Signaling* , 2013, The Journal of Biological Chemistry.

[22]  G. Fonarow,et al.  Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins. , 2013, The American journal of cardiology.

[23]  Zhi-min Xu,et al.  The relationship between serum amyloid A and apolipoprotein A‐I in high‐density lipoprotein isolated from patients with coronary heart disease , 2013, Chinese medical journal.

[24]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[25]  T. van der Poll,et al.  High Levels of S100A8/A9 Proteins Aggravate Ventilator-Induced Lung Injury via TLR4 Signaling , 2013, PloS one.

[26]  A. Perraud,et al.  The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity and inflammation , 2013, Immunologic research.

[27]  D. Levy,et al.  Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[28]  Sean P. Palecek,et al.  Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions , 2012, Nature Protocols.

[29]  R. Baumgartner,et al.  A combined proteomic and genetic analysis of the highly variable platelet proteome: from plasmatic proteins and SNPs. , 2012, Journal of proteomics.

[30]  J. Moreno-Navarrete,et al.  Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. , 2012, European journal of endocrinology.

[31]  M. Andrassy,et al.  S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-kB signaling , 2012 .

[32]  T. Funahashi,et al.  High serum S100A8/A9 levels and high cardiovascular complication rate in type 2 diabetics with ultrasonographic low carotid plaque density. , 2012, Diabetes research and clinical practice.

[33]  Sean P. Palecek,et al.  Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling , 2012, Proceedings of the National Academy of Sciences.

[34]  A. Slöetjes,et al.  Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. , 2012, Arthritis and rheumatism.

[35]  M. Fujita,et al.  S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. , 2012, International journal of cardiology.

[36]  M. Andrassy,et al.  S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling , 2012, Basic Research in Cardiology.

[37]  T. Mcclanahan,et al.  Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease , 2012, Clinical and Translational Gastroenterology.

[38]  Brian D Halligan,et al.  Visualize: A free and open source multifunction tool for proteomics data analysis , 2011, Proteomics.

[39]  Ángel García,et al.  Proteins Involved in Platelet Signaling Are Differentially Regulated in Acute Coronary Syndrome: A Proteomic Study , 2010, PloS one.

[40]  Z. Bosnjak,et al.  Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors , 2010, BMC Developmental Biology.

[41]  Yongmei Liu,et al.  Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study , 2009 .

[42]  E. Tremoli,et al.  Proteome of platelets in patients with coronary artery disease. , 2010, Experimental hematology.

[43]  V. Tesar,et al.  Plasma calprotectin in chronically dialyzed end-stage renal disease patients , 2010, Inflammation Research.

[44]  H. Dauerman,et al.  Platelet functions beyond hemostasis , 2009, Journal of thrombosis and haemostasis : JTH.

[45]  C. Francis,et al.  Platelet proteome changes associated with diabetes and during platelet storage for transfusion. , 2009, Journal of proteome research.

[46]  G. Lip,et al.  Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure , 2009, Annals of medicine.

[47]  A C C Gibbs,et al.  Data Analysis , 2009, Encyclopedia of Database Systems.

[48]  Saeid Ghavami,et al.  S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase‐dependent pathway , 2008, Journal of leukocyte biology.

[49]  K. Walley,et al.  S100A8 and S100A9 Mediate Endotoxin-Induced Cardiomyocyte Dysfunction via the Receptor for Advanced Glycation End Products , 2008, Circulation research.

[50]  Z. Massy,et al.  Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. , 2008, European heart journal.

[51]  P. Libby,et al.  Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. , 2008, American heart journal.

[52]  G. Lip,et al.  Platelet activation in acute, decompensated congestive heart failure. , 2007, Thrombosis research.

[53]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[54]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[55]  P. Libby,et al.  Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events , 2006, Circulation.

[56]  S. Reis,et al.  Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.

[57]  J. Bauersachs,et al.  Platelet activation in heart failure. , 2004, Clinical laboratory.

[58]  W. Daniel,et al.  Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure , 2003, European journal of heart failure.

[59]  V. Hasselblad,et al.  Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? , 2003, American heart journal.

[60]  Z. Bosnjak,et al.  Biphasic Effects of Isoflurane on the Cardiac Action Potential: An Ionic Basis for Anesthetic-induced Changes in Cardiac Electrophysiology , 2002, Anesthesiology.

[61]  V. Hasselblad,et al.  Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes? ☆ ☆☆ ★ ★★ , 2002 .

[62]  M. Andreassi,et al.  Up‐regulation of ‘clearance’ receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones , 2001, European journal of heart failure.